HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.

Abstract
Once-daily trovafloxacin 200 mg was compared with high-dose amoxicillin, 1 g three times daily, given for 7 to 10 days. At end of treatment (day 10), the response was clinically successful (cure + improvement) in 93% of 152 clinically evaluable trovafloxacin patients and in 89% of 160 amoxicillin patients. At study end (day 35), respective rates were 91% and 81% (95% confidence interval: 1.6, 17.6; P=0.01). In evaluable patients with positive baseline radiographs, 93% of trovafloxacin and 88% of amoxicillin patients demonstrated radiological resolution at end of treatment. Streptococcus pneumoniae and Haemophilus influenzae eradication rates were comparable at end of treatment in both treatment groups, but at study end Streptococcus pneumoniae eradication rates were higher in trovafloxacin patients (100% vs 81%). At study end, all four trovafloxacin patients with baseline penicillin-resistant Streptococcus pneumoniae were clinically cured with pathogen eradication, whereas two of five amoxicillin patients with baseline penicillin-resistant Streptococcus pneumoniae were clinical failures with pathogen persistence. For patients in whom no pathogen was identified, trovafloxacin was significantly more effective at end of treatment (P=0.096) and study end (P=0.013). Treatment-related adverse events were comparable; the most common were headache, vomiting and dizziness in trovafloxacin patients, and diarrhoea. headache and abdominal pain in amoxicillin patients.
AuthorsF Trémolières, F de Kock, N Pluck, R Daniel
JournalEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Eur J Clin Microbiol Infect Dis) Vol. 17 Issue 6 Pg. 447-53 (Jun 1998) ISSN: 0934-9723 [Print] GERMANY
PMID9758291 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Infective Agents
  • Fluoroquinolones
  • Naphthyridines
  • Penicillins
  • Amoxicillin
  • trovafloxacin
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Amoxicillin (administration & dosage, adverse effects, therapeutic use)
  • Anti-Infective Agents (administration & dosage, adverse effects, therapeutic use)
  • Community-Acquired Infections (drug therapy)
  • Drug Administration Schedule
  • Female
  • Fluoroquinolones
  • Haemophilus Infections (drug therapy, microbiology)
  • Haemophilus influenzae (drug effects)
  • Humans
  • Male
  • Middle Aged
  • Naphthyridines (administration & dosage, adverse effects, therapeutic use)
  • Penicillins (administration & dosage, adverse effects, therapeutic use)
  • Pneumonia, Bacterial (drug therapy, microbiology)
  • Pneumonia, Pneumococcal (drug therapy, microbiology)
  • Streptococcus pneumoniae (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: